Keywords: Mochida, Fuji Pharma, Biosimilar filgrastim, Japan, GlaxoSmithKline, M&S. GSK Consumer Nigeria, India Consumer Healthcare, UCB, Exemed, India, NewBridge, AfMET
News briefs: Japan clears filgrastim biosimilar; GSK to up stake in Nigerian and Indian firms; UCB deals
Article | 26 November 2012
Mid-sized Japanese drugmaker Mochida Pharmaceutical (TYO: 4534) says that it has received marketing authorization from Japan’s Ministry of ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Negative US patent ruling for Novo Nordisk on Prandin
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Daiichi Sankyo files for Japanese approval of Prasugrel
